health-and-science2 hours ago
Personalized mRNA Melanoma Vaccine Cuts Recurrence Risk by 42%, Triggering Market Volatility
Merck and Moderna released early Phase 3 data for intismeran autogene, a personalized mRNA vaccine that reduces melanoma recurrence risk by 42% when combined with Keytruda. While oncologists praised the efficacy, the premature disclosure caused Moderna’s stock to drop 18%, as investors reacted to results that were slightly lower than earlier trial expectations.